BURLINGAME, Ca. -- Directors of the California stem cell agency are being briefed on their grants that are most likely to develop into commercial stem cell cures in the near future -- meaning at least a number of years down the road.
Here is a link to the lengthy Power Point presentations being used. No additional document is available on the status of the translational portfolio.
Showing posts with label strategic review. Show all posts
Showing posts with label strategic review. Show all posts
Wednesday, October 09, 2013
Thursday, April 29, 2010
CIRM Receives Another $112 Million
Alan Trounson, president of the California stem cell agency, last night outlined his priorities, provided more details on a key strategic review of its program and sketched out upcoming CIRM events.
Directors were also told that the agency received an additional $112 million as the result of recent California state bond sales. That should ensure CIRM has enough cash to operate until the end of 2011. Bonds are virtually the only source of cash for the agency, but they flow directly to CIRM untouched by the governor or legislature.
CIRM has posted Trounson's slide presentations on its Web site. Also included are biographies of scientists who will participate in the strategic review. You can find Trounson's presentation here, budget information here and the biographies here.
Directors were also told that the agency received an additional $112 million as the result of recent California state bond sales. That should ensure CIRM has enough cash to operate until the end of 2011. Bonds are virtually the only source of cash for the agency, but they flow directly to CIRM untouched by the governor or legislature.
CIRM has posted Trounson's slide presentations on its Web site. Also included are biographies of scientists who will participate in the strategic review. You can find Trounson's presentation here, budget information here and the biographies here.
Subscribe to:
Posts (Atom)